Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZED1227 in NAFLD with significant fibrosis (phase II dose-finding)
2021-002253-29Phase 2Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ZED1227 in metabolic dysfunction-associated steatotic liver disease (MASLD) and hepatic fibrosis (4 arms), sponsored by Dr. Falk Pharma GmbH. Primary endpoint: Relative change in serum PRO-C3. Started Dec 2021; status: completed.
02
Drugs
ZED1227
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)hepatic fibrosis
Beyond the preview
Go deeper on 2021-002253-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002253-29.